Catalyst Pharmaceuticals, Inc.
Florida
United States
375 articles about Catalyst Pharmaceuticals, Inc.
-
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
4/22/2024
Catalyst Pharmaceuticals, Inc. announced that it will release its first quarter 2024 financial results after the market close on Wednesday, May 8, 2024.
-
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
3/27/2024
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX) today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.
-
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
3/14/2024
Santhera Pharmaceuticals is pleased to note the launch of AGAMREE® for the treatment of Duchenne muscular dystrophy in the United States by Catalyst Pharmaceuticals, Inc., the Company’s commercialization partner for North America.
-
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
3/13/2024
Catalyst Pharmaceuticals, Inc. today announced the U.S. commercial launch of AGAMREE® (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne Muscular Dystrophy ("DMD") in patients aged two years and older.
-
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
3/5/2024
Catalyst Pharmaceuticals, Inc. today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conference.
-
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/28/2024
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported financial results for the fourth quarter and full year 2023 and provided a business update.
-
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
2/27/2024
Catalyst Pharmaceuticals, Inc. today announced an upcoming poster at the upcoming 2024 MDA Clinical & Scientific Conference taking place March 3-6 in Orlando.
-
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
2/21/2024
Catalyst Pharmaceuticals, Inc. today announced that the peer-reviewed journal Neurology has published Santhera Pharmaceutical's ("Santhera") study titled “ Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy”.
-
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
2/14/2024
Catalyst Pharmaceuticals, Inc. today announced that it will release its fourth quarter and full-year 2023 financial results after the market close on February 28, 2024.
-
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering - Jan 09, 2024
1/9/2024
Catalyst Pharmaceuticals, Inc. reported that it has closed its underwritten public offering of shares of its common stock.
-
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
1/5/2024
Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share.
-
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
1/4/2024
Catalyst Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering of $150,000,000 of its common stock.
-
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
12/18/2023
Catalyst Pharmaceuticals, Inc. today announced that its collaboration partner, DyDo Pharma, Inc. ("DyDo"), reported that it has submitted a New Drug Application (“NDA”) to Japan's Pharmaceuticals and Medical Devices Agency (“PMDA”) seeking marketing approval for FIRDAPSE.
-
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
12/4/2023
Catalyst Pharmaceuticals, Inc. today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024.
-
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
11/16/2023
Catalyst Pharmaceuticals, Inc. today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Piper Sandler 35th Annual Healthcare Conference.
-
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
11/8/2023
Catalyst Pharmaceuticals, Inc. reported financial results for the third quarter of 2023 and provided a corporate update.
-
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio
11/2/2023
Catalyst Pharmaceuticals, Inc. announced that the Company has received notification by the United States Patent and Trademark Office that two additional patents covering FIRDAPSE® Tablets 10 mg, were allowed and will be granted within the next two months.
-
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
10/30/2023
Catalyst Pharmaceuticals, Inc. announced that Catalyst will participate in the upcoming 11th Annual Epilepsy Awareness Day & Education Expo, taking place at the Disneyland Hotel in Anaheim, CA, October 30-31, 2023, to raise awareness and education with the epilepsy community.
-
Santhera Pharmaceuticals and partner Catalyst Pharmaceuticals got the FDA’s greenlight for their Duchenne muscular dystrophy drug Agamree, which is expected to launch in the first quarter of 2024.
-
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
10/23/2023
Catalyst Pharmaceuticals, Inc. today announced that it will release its third-quarter 2023 financial results after market close on Wednesday, November 8, 2023.